253 related articles for article (PubMed ID: 23847367)
21. CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia.
Pardanani A; Lasho TL; Laborde RR; Elliott M; Hanson CA; Knudson RA; Ketterling RP; Maxson JE; Tyner JW; Tefferi A
Leukemia; 2013 Sep; 27(9):1870-3. PubMed ID: 23604229
[TBL] [Abstract][Full Text] [Related]
22. Atypical CML with mutated SRSF2, ASXL1, CSF3R, and MPL.
Tran A; Wong M
Blood; 2021 Dec; 138(26):2890. PubMed ID: 34967865
[No Abstract] [Full Text] [Related]
23. CSF3R T618I, SETBP1 G870S, SRSF2 P95H, and ASXL1 Q780* tetramutation co-contribute to myeloblast transformation in a chronic neutrophilic leukemia.
Qian Y; Chen Y; Li X
Ann Hematol; 2021 Jun; 100(6):1459-1461. PubMed ID: 33822276
[TBL] [Abstract][Full Text] [Related]
24. Inherited transmission of the CSF3R T618I mutational hotspot in familial chronic neutrophilic leukemia.
Duployez N; Willekens C; Plo I; Marceau-Renaut A; de Botton S; Fenwarth L; Boyer T; Huet G; Nibourel O; Rose C; Nelken B; Quesnel B; Preudhomme C
Blood; 2019 Dec; 134(26):2414-2416. PubMed ID: 31697825
[No Abstract] [Full Text] [Related]
25. ASXL1 mutations are frequent and prognostically detrimental in CSF3R-mutated chronic neutrophilic leukemia.
Elliott MA; Pardanani A; Hanson CA; Lasho TL; Finke CM; Belachew AA; Tefferi A
Am J Hematol; 2015 Jul; 90(7):653-6. PubMed ID: 25850813
[TBL] [Abstract][Full Text] [Related]
26. Coexisting of bone marrow fibrosis, dysplasia and an X chromosomal abnormality in chronic neutrophilic leukemia with CSF3R mutation: a case report and literature review.
Wu XB; Wu WW; Zhou Y; Wang X; Li J; Yu Y
BMC Cancer; 2018 Mar; 18(1):343. PubMed ID: 29587671
[TBL] [Abstract][Full Text] [Related]
27. Coexistence of multiple myeloma and a CSF3R-mutated myeloid neoplasm.
Stewart W; Hinton R; Bain BJ
Am J Hematol; 2021 Nov; 96(11):1539-1540. PubMed ID: 34028856
[No Abstract] [Full Text] [Related]
28. Atypical Chronic Myeloid Leukemia in Two Pediatric Patients.
Freedman JL; Desai AV; Bailey LC; Aplenc R; Burnworth B; Zehentner BK; Teachey DT; Wertheim G
Pediatr Blood Cancer; 2016 Jan; 63(1):156-9. PubMed ID: 26274939
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.
Dao KT; Gotlib J; Deininger MMN; Oh ST; Cortes JE; Collins RH; Winton EF; Parker DR; Lee H; Reister A; Schultz ; Savage S; Stevens ; Brockett C; Subbiah N; Press RD; Raess PW; Cascio M; Dunlap J; Chen Y; Degnin C; Maxson JE; Tognon CE; Macey T; Druker BJ; Tyner JW
J Clin Oncol; 2020 Apr; 38(10):1006-1018. PubMed ID: 31880950
[TBL] [Abstract][Full Text] [Related]
30. Chronic neutrophilic leukemia (CNL) with karyotypic abnormalities associated with plasma cell dyscrasia: a case report.
Masini L; Salvarani C; Macchioni P; Baldi G; Rossi F; Croci G; Prandi S; Davoli C; Portioli I; Gobbi F
Haematologica; 1992; 77(3):277-9. PubMed ID: 1427435
[TBL] [Abstract][Full Text] [Related]
31. Current strategies in the diagnosis and management of chronic neutrophilic leukemia.
Otgonbat A; Zhao M
Chin Med J (Engl); 2014; 127(24):4258-62. PubMed ID: 25533830
[TBL] [Abstract][Full Text] [Related]
32. Analysis of gene mutation characteristics in patients with chronic neutrophilic leukaemia.
Yin B; Chen X; Gao F; Li J; Wang HW
Hematology; 2019 Dec; 24(1):538-543. PubMed ID: 31315541
[No Abstract] [Full Text] [Related]
33. CSF3R, SETBP1 and CALR mutations in chronic neutrophilic leukemia.
Cui Y; Li B; Gale RP; Jiang Q; Xu Z; Qin T; Zhang P; Zhang Y; Xiao Z
J Hematol Oncol; 2014 Oct; 7():77. PubMed ID: 25316523
[TBL] [Abstract][Full Text] [Related]
34. Chronic neutrophilic leukemia: 2020 update on diagnosis, molecular genetics, prognosis, and management.
Szuber N; Elliott M; Tefferi A
Am J Hematol; 2020 Feb; 95(2):212-224. PubMed ID: 31769070
[TBL] [Abstract][Full Text] [Related]
35. The CSF3R T618I mutation as a disease-specific marker of atypical CML post allo-SCT.
Langabeer SE; McCarron SL; Haslam K; O'Donovan MT; Conneally E
Bone Marrow Transplant; 2014 Jun; 49(6):843-4. PubMed ID: 24614839
[No Abstract] [Full Text] [Related]
36. [Chronic neutrophilic leukemia with CSF3R mutation and concurrent multiple myeloma: one case report].
He M; Zhao XC; Bai H
Zhonghua Xue Ye Xue Za Zhi; 2019 Dec; 40(12):1052. PubMed ID: 32023742
[No Abstract] [Full Text] [Related]
37. Janus kinases promote cell-surface expression and provoke autonomous signalling from routing-defective G-CSF receptors.
Meenhuis A; Irandoust M; Wölfler A; Roovers O; Valkhof M; Touw IP
Biochem J; 2009 Feb; 417(3):737-46. PubMed ID: 18922133
[TBL] [Abstract][Full Text] [Related]
38. Clinical response to ruxolitinib in CSF3R T618-mutated chronic neutrophilic leukemia.
Stahl M; Xu ML; Steensma DP; Rampal R; Much M; Zeidan AM
Ann Hematol; 2016 Jun; 95(7):1197-200. PubMed ID: 27068405
[No Abstract] [Full Text] [Related]
39. Next-generation sequencing reveals unique combination of mutations in cis of CSF3R in atypical chronic myeloid leukemia.
Yun JW; Yoon J; Jung CW; Lee KO; Kim JW; Kim SH; Kim HJ
J Clin Lab Anal; 2020 Feb; 34(2):e23064. PubMed ID: 31692115
[TBL] [Abstract][Full Text] [Related]
40. Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent
Gunawan AS; McLornan DP; Wilkins B; Waghorn K; Hoade Y; Cross NCP; Harrison CN
Haematologica; 2017 Jun; 102(6):e238-e240. PubMed ID: 28302714
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
